-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D+PapjtOvRHrE1epfkNEBA9nbLH5H2A7Ke5aVB4eSF9Wsykl/5KEFVv1kyXIQQDQ URpWjUOW7cgfPwUpfqyAdg== 0000898432-08-000141.txt : 20080214 0000898432-08-000141.hdr.sgml : 20080214 20080214171544 ACCESSION NUMBER: 0000898432-08-000141 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080214 DATE AS OF CHANGE: 20080214 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS L.P. GROUP MEMBERS: INVESTMENT 10, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MIGENIX Inc. CENTRAL INDEX KEY: 0000915458 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-78624 FILM NUMBER: 08618843 BUSINESS ADDRESS: STREET 1: 1750 609 GRANVILLE ST CITY: VANCOUVER B C CANADA STATE: A1 ZIP: 00000 BUSINESS PHONE: (604) 221-9666 MAIL ADDRESS: STREET 1: BC RESEARCH COMPLEX STREET 2: 3650 WESBROOK MALL CITY: VANCOUVER STATE: A1 ZIP: V6S2L2 FORMER COMPANY: FORMER CONFORMED NAME: MICROLOGIX BIOTECH INC DATE OF NAME CHANGE: 19931129 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 SC 13G/A 1 sc13ga.htm


SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)

(Amendment No. 1)*

MIGENIX INC.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)


 

59861R104

(CUSIP Number)


 

December 31, 2007

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

 

o Rule 13d-1(b)
ý Rule 13d-1(c)
o Rule 13d-1(d)



*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 2 of 10 Pages

 

 

 

 

 


 

1

 

 NAME OF REPORTING PERSON:
Biotechnology Value Fund, L.P.
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 Delaware

 

 

 


 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 4,123,803

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 4,123,803

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 4,123,803

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


  4.4%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 PN

 

 




 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 3 of 10 Pages

 

 

 

 

 


 

1

 

 NAME OF REPORTING PERSON:
Biotechnology Value Fund II, L.P.
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 


 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 2,477,493

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 2,477,493

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 2,477,493

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 


11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 2.6%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


PN

 

 

 

 

 

 

 




 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 4 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
BVF Investments, L.L.C.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 7,979,710

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 7,979,710


 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 7,979,710

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 8.5%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 OO

 

 

 





 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 5 of 10 Pages

 

 

 

 

 

 


 

1

 

 NAME OF REPORTING PERSON:
Investment 10, L.L.C.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 


 


 Illinois


 


 

 


 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

896,994

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 896,994

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 896,994

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 1.0%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 OO

 

 

 





 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 6 of 10 Pages

 

 

 

 

 

 


1

 

 NAME OF REPORTING PERSON:
BVF Partners L.P.
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 


 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 15,478,000

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 15,478,000

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


 15,478,000

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 16.4%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 PN

 

 

 




CUSIP No. 59861R104

 

13G

 

Page 7 of 10 Pages

 

 

 

 

 

 

 

 

 

 

 

1

 

 NAME OF REPORTING PERSON:
BVF Inc.
 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)  ý

 

 

 

 

(b)  o

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 

 

 


 Delaware

 

 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

15,478,000

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 15,478,000

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 


15,478,000

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

o


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 


 16.4%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 


 IA, CO

 

 

 




 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 8 of 10 Pages


ITEM 1(a).      NAME OF ISSUER:

                         Migenix Inc. (“Migenix”)

ITEM 1(b).      ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

BC Research Building

3650 Westbrook Mall

Vancouver, BC V6S 2L2

Canada



ITEM 2(a).      NAME OF PERSON FILING:

                         This Amendment No. 1 to Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

 

(i)

 

 Biotechnology Value Fund, L.P. ("BVF")

 

(ii)

 

 Biotechnology Value Fund II, L.P. ("BVF2")

 

(iii)

 

 BVF Investments, L.L.C. ("Investments")

 

(iv)

 

 Investment 10, L.L.C. ("ILL10")

 

(v)

 

 BVF Partners L.P. ("Partners")

 

(vi)

 

 BVF Inc. ("BVF Inc.")

ITEM 2(b).      ADDRESS OF PRINCIPAL BUSINESS OFFICE:

                         The principal business office of the Reporting Persons comprising the group filing this Amendment No. 1 to Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.

ITEM 2(c).      CITIZENSHIP:

 

 

 BVF:

 a Delaware limited partnership

 

 

 BVF2:

 a Delaware limited partnership

 

 

 Investments:

 a Delaware limited liability company

 

 

 ILL10:

 an Illinois limited liability company

 

 

 Partners:

 a Delaware limited partnership

 

 

 BVF Inc.:

 a Delaware corporation

ITEM 2(d).      TITLE OF CLASS OF SECURITIES:

                         This Amendment No. 1 to Schedule 13G is being filed with respect to the common stock ("Common Stock"), of Migenix.  The Reporting Persons' percentage ownership of Common Stock is based on (i) 94,463,806 shares of Common Stock being outstanding, and (ii) the beneficial ownership by the Reporting Persons of 12,130 royalty participation units (the “Units”) initially exercisable into 7,278,000 shares of Common Stock.  For a discussion of the Units held by the Reporting Persons, see the Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission (“SEC”) on December 13, 2002, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons with the SEC on or around May 11, 2006.

                 

    As of December 31, 2007, BVF beneficially owned 4,123,803 shares of Common Stock of which 1,587,600 shares are attributable to the Units, BVF2 beneficially owned 2,477,493 shares of Common Stock, of which 1,087,800 are attributable to the Units, Investments beneficially owned 7,979,710 shares of Common Stock of which 4,145,400 shares are attributable to the Units and ILL10 beneficially owned 896,994 shares of Common Stock of which 457,200 shares are attributable to the Units.  Beneficial ownership by Partners and BVF Inc. includes 15,478,000 shares of  Common Stock, of which 7,278,000 shares are attributable to the Units.


ITEM 2(e).      CUSIP Number:

                       59861R104






 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 9 of 10 Pages


ITEM 3.        IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS:    One of the following

                        Not applicable as this Amendment No. 1 to Schedule 13G is filed pursuant to Rule 13d-1(c).

ITEM 4.        OWNERSHIP:

                        The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Amendment No. 1 to Schedule 13G is hereby incorporated by reference.

ITEM 5.        OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

                        If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. 

ITEM 6.        OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

                        Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in shares of the Common Stock beneficially owned by Investments and to vote and exercise dispositive power over those shares of the Common Stock. Partners and BVF Inc. share voting and dispositive power over shares of the Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as an investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of the Common Stock owned by such parties.

ITEM 7.        IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

                        Not applicable.

ITEM 8.        IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:

                        Not applicable.

ITEM 9.        NOTICE OF DISSOLUTION OF GROUP:

                        Not applicable.




 

 

 

 

 

CUSIP No. 59861R104

 

13G

 

Page 10 of 10 Pages


ITEM 10.        CERTIFICATION

                        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

                        After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:

 

February 14, 2008



 


 


BIOTECHNOLOGY VALUE FUND, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


/s/ Mark N. Lampert

 

 

 

 

 

 

 

 

Mark N. Lampert
President


 


 


BIOTECHNOLOGY VALUE FUND II, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

Mark N. Lampert
President


 


 


BVF INVESTMENTS, L.L.C.


 


 


By:


 


BVF Partners L.P., its manager


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


/s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert
President



 


 


INVESTMENT 10, L.L.C.


 


 


By:


 


BVF Partners L.P., its attorney-in-fact


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


/s/ Mark N. Lampert

 

 

 

 

 

 

 

 

Mark N. Lampert
President


 


 


BVF PARTNERS L.P.


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


/s/ Mark N. Lampert

 

 

 

 

 

 

 

 


Mark N. Lampert
President


 


 



BVF INC.


 


 


 


 


 


 


By:


 


/s/ Mark N. Lampert

 

 

 

 

 

 

 

 

Mark N. Lampert
President






 -----END PRIVACY-ENHANCED MESSAGE-----